Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620746 | 0.85 | CHRNB2 (0.40) | CHRNB2CHRNA4SIGMAR1BRD4CREBBP | |
| SCHEMBL31659540 | 0.78 | CHRNB2 (0.36) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL27010622 | 0.77 | ROCK2 (0.34) | CHRNB2CHRNA4SIGMAR1MTNR1AMTNR1B | |
| SCHEMBL2620988 | 0.75 | BRD4 (0.55) | MTNR1AMTNR1BBRD4CREBBPMAPT | |
| SCHEMBL8986731 | 0.75 | BRD4 (0.55) | MTNR1AMTNR1BBRD4CREBBPMAPT | |
| SCHEMBL9965445 | 0.75 | BRD4 (0.55) | MTNR1AMTNR1BBRD4CREBBPMAPT | |
| SCHEMBL13291916 | 0.74 | SIGMAR1 (0.46) | CHRNB2CHRNA4SIGMAR1BRD4CREBBP | |
| SCHEMBL29012624 | 0.74 | GABRP (0.38) | CHRNB2CHRNA4SIGMAR1MTNR1AMTNR1B | |
| SCHEMBL30887799 | 0.74 | CYP1A2 (0.39) | CHRNB2CHRNA4SIGMAR1CYP11B1CYP11B2 | |
| SCHEMBL28308572 | 0.74 | CYP1A2 (0.39) | CHRNB2CHRNA4SIGMAR1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CHRNB2 3404/4885CHRNA4 3102/4885SIGMAR1 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.